Skip to main content
Richard Stone, MD, Oncology, Boston, MA

RichardMauryStoneMD

Oncology Boston, MA

Professor of Medicine, Dana-Farber Cancer Institute

Dr. Stone is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Stone's full profile

Already have an account?

  • Office

    44 Binney St
    Boston, MA 02115
    Phone+1 617-632-2214
    Fax+1 617-632-2933

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1984 - 1987
  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Internal Medicine, 1981 - 1984
  • Harvard Medical School
    Harvard Medical SchoolClass of 1981

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2022 - Present
  • NH State Medical License
    NH State Medical License 2024 - 2026
  • RI State Medical License
    RI State Medical License 2022 - 2026
  • VT State Medical License
    VT State Medical License 2023 - 2026
  • MA State Medical License
    MA State Medical License 1984 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Super Doctor SuperDoctors.com

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML  
    Daniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine
  • NF1 Mutations Are Recurrent in Adult Acute Myeloid Leukemia and Confer Poor Outcome  
    Eunice S Wang, Bayard L Powell, Richard M Stone, John C Byrd, Clara D Bloomfield, Alice Mims, Andrew J Carroll, Jonathan E Kolitz, James S Blachly, Nature

Abstracts/Posters

  • Tolerability and Efficacy of Crenolanib and Cytarabine/Anthracycline Chemotherapy in Older Patients (Aged 61 to 75) with Newly Diagnosed FLT3-Mutated Acute Myeloid Leu...
    Richard M. Stone, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Feasibility and Impact of Embedded Geriatric Consultation for Frail Older Adults with Blood Cancer: A Randomized Controlled Trial
    Richard M. Stone, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for Untreated BCR-ABL1-Positive ALL in Older Adults
    Richard Stone, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Crenolanib versus midostaurin combined with induction and consolidation chemotherapy in newly diagnosed mutated AML. 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
  • Data + Perspectives: Exploring the Role of Novel Agents and Emerging Strategies in the Management of Acute Myeloid Leukemia 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Pre... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Join now to see all

Other

Authored Content

  • Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 MutationJune 2017

Press Mentions

  • Could Aspirin Avert Bad Outcomes in Leukemia?
    Could Aspirin Avert Bad Outcomes in Leukemia?September 9th, 2024
  • Journal Honors Rahul S. Vedula, MD, as Recipient of the 2020 Journal of Clinical Oncology Young Investigator Award
    Journal Honors Rahul S. Vedula, MD, as Recipient of the 2020 Journal of Clinical Oncology Young Investigator AwardJune 25th, 2020
  • Genomic Advances Pave the Way for New Therapies in AML
    Genomic Advances Pave the Way for New Therapies in AMLMarch 1st, 2017

Grant Support

  • Third Bone Marrow Failure Disease Scientific SymposiumNational Heart, Lung, And Blood Institute2012
  • Clinical Trails In Myeloid Maliganancies With Molecularly Targeted TherapiesNational Cancer Institute2008–2012
  • Aa&Mdsif Second Bone Marrow Failure Disease Scientific SymposiumNational Heart, Lung, And Blood Institute2009
  • Core--Clinical Research Support ComponentNational Cancer Institute2002
  • Protein Kinase C Based Antileukemic TherapyNational Cancer Institute1995–1999
  • Differentiation Signal Transduction In Myeloid LeukemiaNational Cancer Institute1990–1994

Professional Memberships